EcoDrugPlus

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSMZEG00005007507
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSMZEG00005022397
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSMZEG00005002550
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSMZEG00005025083
Gene Symbol: CHRM5A
1 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSMZEG00005009671
Gene Symbol: CHRM5A
2 Cross references
192 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSMZEG00005014966
Gene Symbol: F2R
1 Cross references
216 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMZEG00005006884
Gene Symbol: F2R
4 Cross references
249 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMZEG00005006871
Gene Symbol: F2R
2 Cross references
247 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMZEG00005006898
Gene Symbol: F2R
2 Cross references
248 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMZEG00005006911
Gene Symbol: F2R
4 Cross references
248 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSMZEG00005014708
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSMZEG00005012111
Gene Symbol: LOC101466849
3 Cross references
78 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).